Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 5/20 | 0.49 |
| ▸ | MMP2 | P08253 | 5/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837984 | 1.00 | ANPEP (0.50) | ANPEPMMP3MMP2MMP8CTSL | |
| SCHEMBL3840255 | 0.88 | CAPN1 (0.58) | MMP2MMP12MMP13MME | |
| SCHEMBL20474454 | 0.88 | CAPN1 (0.58) | MMP2MMP12MMP13MME | |
| SCHEMBL20474455 | 0.88 | CAPN1 (0.58) | MMP2MMP12MMP13MME | |
| SCHEMBL21457982 | 0.87 | CAPN1 (0.62) | CTSL | |
| SCHEMBL4390231 | 0.87 | CAPN1 (0.62) | CTSL | |
| SCHEMBL15304656 | 0.84 | CAPN1 (0.53) | ANPEPMMP3MMP2CTSLMMP1 | |
| SCHEMBL21457995 | 0.84 | CAPN1 (0.64) | ANPEPMMP3MMP2MMP8CTSL | |
| SCHEMBL3844110 | 0.84 | CAPN1 (0.64) | ANPEPMMP3MMP2MMP8CTSL | |
| SCHEMBL21458071 | 0.83 | MMP1 (0.44) | ANPEPMMP3MMP2MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | ANPEP 4220/4885MMP3 3124/4885MMP2 2186/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | ANPEP 4220/4885MMP3 3124/4885MMP2 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.